Alzamend Neuro, Inc. (ALZN) News
Filter ALZN News Items
ALZN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ALZN News Highlights
- ALZN's 30 day story count now stands at 4.
- Over the past 25 days, the trend for ALZN's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about ALZN are DRUG.
Latest ALZN News From Around the Web
Below are the latest news stories about ALZAMEND NEURO INC that investors may wish to consider to help them evaluate ALZN as an investment opportunity.
EXCLUSIVE: Alzamend Neuro Plans To Kickstart Stress Disorder Study With Next-Gen Lithium Product Next YearAlzamend Neuro Inc (NASDAQ: ALZN) received a "Study May Proceed" letter from the FDA for the initiation of study AL001-PTSD01, a Phase 2A study of AL001 for post-traumatic stress disorder (PTSD). "Although lithium does not have an FDA-approved indication for PTSD, it has been prescribed off-label for this purpose for decades," said Stephan Jackman, Chief Executive Officer of Alzamend. "If we can develop a next-generation lithium product (AL001) that would not routinely require therapeutic drug m |
Alzamend Neuro Receives FDA "Study May Proceed" Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder PatientsATLANTA, December 11, 2023--Alzamend Neuro Receives FDA "Study May Proceed" Notice for Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug to Treat PTSD |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayIt's time to start Tuesday trading with a breakdown of the biggest pre-market stock movers worth keeping an eye on this morning! |
Alzamend Neuro Receives FDA "Study May Proceed" Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder PatientsATLANTA, November 20, 2023--Alzamend Gets FDA "Study May Proceed" Notice for Phase IIA Clinical Trial of AL001 a Next-Generation Lithium Therapeutic for Major Depressive Disorder |
Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price RequirementATLANTA, November 16, 2023--Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement |
Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Post-Traumatic Stress Disorder Patients of Next‑Generation Lithium Therapeutic Drug Candidate AL001ATLANTA, November 13, 2023--Alzamend Neuro Submits IND Application for Phase IIA Clinical Trial of a Next-Generation Lithium Therapeutic Drug AL001; Targeting Patients with PTSD |
Alzamend Neuro Announces Reverse Stock SplitATLANTA, October 30, 2023--Alzamend Neuro Announces Reverse Stock Split |
EXCLUSIVE: Alzamend Neuro Submits IND For Phase IIA Trial Of Next-Gen Lithium Candidate In Major Depressive DisorderAlzamend Neuro Inc (NASDAQ: ALZN) has submitted an investigational new drug (IND) application to the FDA to initiate AL001-MDD01, a Phase IIA plasma/brain pharmacokinetics clinical study of AL001 for adjunctive treatment of patients with major depressive disorder (MDD). Alzamend Neuro is a clinical-stage biopharmaceutical company focused on developing novel products for treating Alzheimer’s, BD, MDD, and PTSD. Lithium, although not FDA-approved for MDD augmentation, has been used off-label for y |
Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Major Depressive Disorder Patients of its Next‑Generation Lithium Therapeutic Drug Candidate AL001ATLANTA, October 23, 2023--Alzamend Neuro Submit IND Application for Phase IIA Clinical Trial for Major Depressive Disorder of Its Next-Generation Lithium Therapeutic Drug AL001 |
EXCLUSIVE: Alzamend Neuro To Start Next-Gen Therapy Study For Bipolar DisorderAlzamend Neuro Inc (NASDAQ: ALZN) received the FDA's "Study May Proceed" letter to initiate study AL001-BD01, a Phase 2A clinical study of AL001 for bipolar disorder type 1. The company expects the first patient to be dosed in the first quarter of 2024. Also Read: EXCLUSIVE: Alzamend Seeks FDA Approval For Study For Upgraded Version Of Most Commonly Used Treatment For Bipolar Disorder. As a follow-up to our "IND submission" release in August, the FDA has granted us a "Study May Proceed" notifica |